What is ThinkCyte?
ThinkCyte operates at the intersection of hardware engineering, machine learning, and biotechnology. Headquartered in Tokyo, the firm specializes in developing transformational single-cell technologies designed to accelerate biological discoveries. By integrating multidisciplinary platforms, ThinkCyte provides biomedical professionals with the tools necessary to advance novel treatments and diagnostics. The company's market position is defined by its ability to bridge the gap between complex data analysis and practical clinical application, effectively serving the needs of researchers and healthcare providers globally. Its commitment to innovation has made it a focal point for venture capital firms and financial institutions looking to capitalize on the next generation of life science infrastructure.
How much funding has ThinkCyte raised?
ThinkCyte has raised a total of $97.3M across 4 funding rounds:
Series A
$15.3M
Series B
$26M
Private Equity
$24M
Series C
$32M
Series A (2020): $15.3M with participation from Fuyo General Lease, SBI Group, SPARX Group, and Itochu Technology Ventures, Inc
Series B (2021): $26M led by Sysmex, SBI Group, ITOCHU Technology Ventures, Mirai Creation Fund/SPARX Asset Management, and Sumitomo Mitsui Trust Investment Co.
Private Equity (2023): $24M supported by Tokyo Century, Nomura Holdings, and Sumitomo Mitsui Trust Bank
Series C (2024): $32M featuring SMBC Venture Capital
Key Investors in ThinkCyte
SMBC Venture Capital
SMBC Venture Capital is a prominent financial institution operating within the venture capital and private equity landscape, providing essential growth capital to high-potential technology firms.
Tokyo Century
Tokyo Century is a specialized financial services firm that integrates equipment leasing and specialty financing to support the corporate growth and strategic goals of its partners.
Nomura Holdings
Nomura is a leading Asia-based financial services group with a comprehensive global network, offering integrated investment banking and asset management solutions to institutional clients.
What's next for ThinkCyte?
With the successful closure of its recent financing round, ThinkCyte is well-positioned to scale its operations and expand the reach of its single-cell diagnostic platforms. The strategic deployment of this capital will likely focus on accelerating the commercialization of its core technologies and deepening its research capabilities. As the company transitions into its next phase of growth, it is expected to prioritize international market penetration and the formation of strategic partnerships with global healthcare entities. By maintaining its focus on high-impact biomedical solutions, ThinkCyte aims to solidify its role as a foundational provider of diagnostic intelligence, ultimately driving long-term value for its stakeholders and the broader scientific community.
See full ThinkCyte company page
